Biofilm Eradication of <i>Stenotrophomonas maltophilia</i> by Levofloxacin and Trimethoprim-Sulfamethoxazole-Reference-Cited by-同舟云学术

Biofilm Eradication of <i>Stenotrophomonas maltophilia</i> by Levofloxacin and Trimethoprim-Sulfamethoxazole

Published:2024-07-31 Issue:4 Volume:77 Page:213-219
ISSN:1344-6304
Container-title:Japanese Journal of Infectious Diseases
language:en
Short-container-title:Jpn J Infect Dis

Author:

Río-Chacón José Mauricio Del¹,Rojas-Larios Fabián¹,Bocanegra-Ibarias Paola²,Salas-Treviño Daniel²,Espinoza-Gómez Francisco¹,Camacho-Ortiz Adrián²,Flores-Treviño Samantha²

Affiliation:

1. Laboratory of Ecology, School of Medicine, University of Colima, Mexico

2. Department of Infectious Diseases, University Hospital Dr. José Eleuterio González and School of Medicine, Autonomous University of Nuevo León, Mexico

Publisher

Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis

Link

https://www.jstage.jst.go.jp/article/yoken/77/4/77_JJID.2023.389/_pdf

Reference33 articles.

1. 1. Mojica MF, Humphries R, Lipuma JJ, et al. Clinical challenges treating Stenotrophomonas maltophilia infections: an update. JAC Antimicrob Resist. 2022;4:dlac040.

2. 2. Herrera-Heredia SA, Pezina-Cantu C, Garza-Gonzalez E, et al. Risk factors and molecular mechanisms associated with trimethoprim-sulfamethoxazole resistance in Stenotrophomonas maltophilia in Mexico. J Med Microbiol. 2017;66:1102-1109.

3. 3. Chang YT, Lin CY, Chen YH, et al. Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options. Front Microbiol. 2015;6:893.

4. 4. Gales AC, Seifert H, Gur D, et al. Antimicrobial susceptibility of Acinetobacter calcoaceticus-Acinetobacter baumannii complex and Stenotrophomonas maltophilia clinical isolates: results from the SENTRY Antimicrobial Surveillance Program (1997–2016). Open Forum Infect Dis. 2019;6:S34-S46.

5. 5. Gibb J, Wong DW. Antimicrobial treatment strategies for Stenotrophomonas maltophilia: a focus on novel therapies. Antibiotics (Basel). 2021;10:1226.